GNTA | Genenta Science S.p.A. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.01 - 5.35
52 Week Range	2.2000 - 7.28
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	4,684
Average Volume	13,744
Shares Outstanding	18,289,866
Market Cap	91,632,229
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-12-15

Valuation
Profitability
Growth
Health
P/E Ratio	-9.82
Forward P/E Ratio	N/A
EPS	-0.51
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	Italy
Website	GNTA

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA's peers: MOLN, MNOV, ANEB, CSBR, CYT, PMVP, ELYM, PHVS, PEPG, MLYS, JANX, RZLT, GLSH, OPT, PRDS, ANTX, AVTE, ADAG, PHAR, STRO, TRDA

*Chart delayed

Analyzing fundamentals for GNTA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see GNTA Fundamentals page.

Watching at GNTA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GNTA Technicals page.